Sequential administration of cisplatin followed by navitoclax, a BCL-2/BCL-XL inhibitor, has shown promising preclinical results by selectively inducing apoptosis in senescent cells, thus potentially reducing the risk of cancer recurrence [89,94]. The gene discussed is BCL2; the disease is cancer.